Dexamethasone for BPD Prevention: Risk-Benefit Analysis in Preterm Neonates

Introduction to Bronchopulmonary Dysplasia and Postnatal Steroids

Bronchopulmonary dysplasia (BPD) is the most prevalent chronic lung disease of infancy, affecting 30 to 50 percent of extremely preterm infants born before 28 weeks of gestation. Defined as the need for supplemental oxygen or respiratory support at 36 weeks postmenstrual age (PMA), BPD results from the complex interaction of pulmonary immaturity, inflammation, oxidative injury, mechanical ventilation-induced damage, and infection. In Indian NICUs, where survival rates for extremely preterm infants are improving, the burden of BPD is increasing, making its prevention and management a clinical priority.

Postnatal dexamethasone has a potent anti-inflammatory effect on the developing lung and can dramatically improve respiratory compliance, facilitate earlier extubation, and reduce BPD rates. However, the history of dexamethasone in neonatology is marked by a pendulum swing: from widespread high-dose use in the 1990s, to near-abandonment following evidence of neurodevelopmental toxicity, to the current nuanced risk-stratified approach using low-dose late protocols. This article provides a comprehensive review of the evidence and practical guidance for Indian neonatal practitioners.

Pharmacology of Dexamethasone

Anti-Inflammatory Mechanisms in BPD

Dexamethasone is a synthetic fluorinated glucocorticoid with 25 to 30 times the anti-inflammatory potency of hydrocortisone and negligible mineralocorticoid activity. In the inflamed preterm lung, dexamethasone suppresses nuclear factor kappa-B (NF-kB) mediated transcription of pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and TNF-alpha. It stabilizes vascular endothelium to reduce pulmonary edema, enhances surfactant protein synthesis and secretion, inhibits leukotriene and prostaglandin production in pulmonary tissue, and promotes alveolar fluid clearance through sodium channel upregulation. These combined effects rapidly improve lung compliance and gas exchange in ventilated preterm neonates.

Pharmacokinetic Profile in Neonates

Parameter	Neonatal Value
Oral bioavailability	78-90%
Plasma half-life	2-5 hours
Biological half-life	36-54 hours
Protein binding	65-75%
Metabolism	Hepatic CYP3A4
Blood-brain barrier penetration	Significant (relevant to neurotoxicity)

The prolonged biological half-life allows once or twice daily dosing. The significant blood-brain barrier penetration is directly relevant to both the neuroinflammatory benefits and the neurodevelopmental toxicity concerns associated with neonatal dexamethasone use.

Historical Context: The Rise and Fall of High-Dose Steroids

During the 1990s, dexamethasone was used liberally in NICUs at doses of 0.5 mg/kg/day, often starting in the first days of life. These high-dose early protocols showed impressive short-term pulmonary benefits but long-term follow-up revealed alarming rates of cerebral palsy, cognitive impairment, and brain volume reduction. The 2002 AAP and Canadian Paediatric Society joint statement recommended against routine early dexamethasone use, effectively curtailing its use. However, this created a clinical vacuum for managing ventilator-dependent preterm infants at high risk of BPD, prompting a more nuanced evidence-based reassessment.

The Risk-Stratified Approach

The seminal meta-regression analysis by Doyle et al. (2005, updated 2014) demonstrated that the net effect of postnatal dexamethasone on death or cerebral palsy depends on the baseline BPD risk. When BPD risk is below 35 percent, dexamethasone increases the combined risk of death or CP. When BPD risk exceeds 50 percent, dexamethasone reduces the combined risk. This threshold-based approach now guides clinical decisions: dexamethasone should only be considered when the estimated BPD risk is sufficiently high that the pulmonary benefits outweigh the neurodevelopmental risks.

DART Protocol: Recommended Low-Dose Regimen

Days	Dose (mg/kg/day)	Frequency
1-3	0.15	Divided q12h, IV or oral
4-6	0.10	Divided q12h, IV or oral
7-8	0.05	Once daily, IV or oral
9-10	0.02	Once daily, IV or oral

The total cumulative dose of approximately 0.89 mg/kg over 10 days is dramatically lower than the 3 to 5 mg/kg cumulative doses of earlier protocols. The DART trial itself was terminated early due to slow enrollment and did not reach its primary outcome endpoint. However, the principle of low-dose late dexamethasone has been adopted as standard practice based on the collective evidence.

Patient Selection Criteria

1. Gestational age below 30 weeks with evolving or established BPD
2. Ventilator-dependent beyond 7 to 14 days of life despite optimal respiratory management including surfactant, caffeine, diuretics, and appropriate ventilator strategies
3. Estimated BPD risk exceeding 50 percent using validated prediction tools
4. Unable to wean from mechanical ventilation despite multiple attempts
5. Echocardiographic exclusion of hemodynamically significant PDA or pulmonary hypertension as primary cause of ventilator dependence
6. Parental informed consent after discussion of risks and benefits

Monitoring During Treatment

• Blood glucose: Every 6 to 12 hours during the first 5 days. Hyperglycemia occurs in 60 to 80 percent of infants and may require insulin infusion.
• Blood pressure: Every 6 to 8 hours. Dexamethasone-induced hypertension may require antihypertensive treatment.
• Growth: Weekly weight, length, and head circumference. Growth velocity typically decreases during steroid course and recovers after discontinuation.
• Infection markers: Clinical surveillance for nosocomial infection. CRP and blood cultures if sepsis suspected, as steroids may mask clinical signs.
• Echocardiography: If hypertension develops or course exceeds 14 days, assess for hypertrophic cardiomyopathy. Steroid-induced HCM is usually reversible within 2 to 4 weeks of discontinuation.
• GI monitoring: Abdominal assessment for perforation signs. Absolutely avoid concurrent indomethacin or ibuprofen use.

Adverse Effects Profile

Short-Term Effects

• Hyperglycemia requiring insulin in many cases
• Systemic hypertension
• Adrenal suppression (provide stress-dose steroids during acute illness within 2 weeks of course completion)
• Poor weight gain during and immediately after treatment
• Increased nosocomial infection risk
• Reversible hypertrophic cardiomyopathy
• GI bleeding or perforation (rare at DART doses but increased with concurrent NSAIDs)

Long-Term Neurodevelopmental Concerns

Animal data demonstrate dexamethasone-induced neuronal apoptosis, impaired hippocampal neurogenesis, and brain volume reduction. In human neonates, early high-dose protocols increased cerebral palsy risk. However, late low-dose protocols have not consistently shown the same degree of neurodevelopmental harm. The DART trial follow-up at 2 years showed no significant increase in CP or NDI, though the study had limited statistical power. Long-term developmental follow-up remains essential for all infants who receive postnatal steroids.

Hydrocortisone as an Alternative

The PREMILOC trial showed that early low-dose hydrocortisone (1 mg/kg/day for 7 days, then 0.5 mg/kg/day for 3 days) started within 24 hours increased BPD-free survival at 36 weeks. Hydrocortisone has lower blood-brain barrier penetration than dexamethasone, potentially offering a better neurodevelopmental safety profile. However, concurrent hydrocortisone and indomethacin use significantly increases intestinal perforation risk. The evidence base for hydrocortisone in BPD prevention is growing but less established than for late dexamethasone.

Indian Practice Context

In Indian NICUs, postnatal dexamethasone use varies considerably. Urban tertiary centres with advanced ventilatory capabilities and established BPD programs tend to follow structured protocols aligned with the DART regimen. Smaller NICUs may have less systematic approaches. The NNF recommends that postnatal corticosteroids be used selectively based on individual risk assessment, using the lowest effective dose and shortest duration, with documented informed consent. HEAMAC respiratory support equipment including neonatal ventilators and CPAP systems helps optimize non-pharmacological respiratory management, potentially reducing the need for steroid intervention.

Conclusion

Dexamethasone for BPD prevention requires careful risk-benefit assessment for each individual patient. The evidence supports late, low-dose use (DART protocol) only in ventilator-dependent preterm infants at high risk of BPD, where the benefits of improved lung function clearly outweigh the potential neurodevelopmental risks. A systematic approach incorporating risk estimation, standardized dosing, comprehensive monitoring, parental counseling, and long-term follow-up is essential for responsible dexamethasone use in Indian NICUs. The goal remains identifying the right drug, at the right dose, for the right patient, at the right time.